The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

Key messagesGREG is a five-year, 26.2 million euros initiative that unites 29 partner organisations to advance Real-World ...

MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

The European Medicines Agency (EMA) has approved Moleculin Biotech’s clinical trial application (CTA) for a pivotal, ...

Investing.com -- Shares of Regenxbio Inc . (NASDAQ: RGNX) climbed 7.2% in premarket trading after the company announced the U.S. Food and Drug Administration (FDA) has accepted for priority review its ...

Ixchiq is the first preventive vaccine against the chikungunya virus authorised in Europe and the US. Among the adverse events included the death of adults aged 62 and 89 years. However, the exact ...

US health authorities have advised elderly people above the age of 60 years to avoid taking Chikungunya vaccine after two ...

Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of ...